Inhibitors targeting epigenetic factors have been explored for cancer therapies and have undergone clinical trials, including DNA methyltransferase 1 inhibitors, histone deacetylase inhibitors, and histone methyltransferase inhibitors [44–46]. The gene discussed is DNMT1; the disease is cancer.